SOLICITATION NOTICE
68 -- Human Genome 3.0 Oligonucleotide sets
- Notice Date
- 12/17/2003
- Notice Type
- Solicitation Notice
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Research Contracts Br., 6120 Executive Blvd. EPS Suite 600, Rockville, MD, 20852
- ZIP Code
- 20852
- Solicitation Number
- NCI-40022-NG
- Response Due
- 12/29/2003
- Archive Date
- 12/29/2003
- Point of Contact
- Malinda Holdcraft, Purchasing Agent, Phone (301) 402-4509, Fax (301) 402-4513, - Renita Smith, Contract Specialist, Phone 301-496-8612, Fax 301-480-0241,
- E-Mail Address
-
holdcram@exchange.nih.gov, rs442i@nih.gov
- Description
- The National Cancer Institute (NCI), Microarray Facility, Advanced Technology Center (ATC) plans to procure on a sole source basis for human genome 3.0 oligonucleotide sets with Qiagen Technologies, Inc. 1000 Atlantic Avenue, Suite 108, Alameda, CA 94501. The supplies and services herein are commercial as defined in FAR Part 12, and this acquisition is being made in accordance with the test program for using simplified procedures for certain commercial items authorized by FAR Part 13. The North American Industry Classification System Code is 422210 and the business size standard is 100 employees. One of the ATC's missions is the manufacturing of quality micro-arrays for comprehensive gene expression analysis, providing training protocols and technical support to NCI researchers and develop new microarray technologies and applications. High density DNA micro-array technology has been used to achieve high throughput analysis of massively parallel genomic sequences. These high density DNA micro-arrays have been used to perform expression studies, re-sequencing experiments, and genotype analysis on the genes of human, mouse, and other organisms. Qiagen is the only known source that can provide the aforementioned oligonucleotides, that can offer large oligonucleotide sets of 70 bases (70 mers) in size that can be used for large scale expression and complex expression studies. Since significant work has been done using Qiagen oligonucleotides, they are believed to be the only ones which will maintain compatibility and allow comparison of experimental results without introducing new variables. This is not a request for competitive request. However, if any interested party believes it can meet the above requirement, it may submit a statement of capabilities. This statement must list all oligonucleotides available and shall specify quality, size, and encompass the genes that make up the oligo set. The capability statement and any other furnished information must be in writing and must contain material in sufficient detail to allow NCI to determine if the party can fully meet the requirement. Capability statements must be received in the contracting office by 1:00 PM EST, (local Washington DC time) on December 29, 2003. If you have any questions, please contact Malinda Holdcraft, Purchasing Agent via electronic mail at holdcram@exchange.nih.gov or by fax at 301-402-4513. A determination by the Government not to compete this proposed requirement based on responses to this notice is solely within the discretion of the Government. Information received shall be considered solely for the purpose of determining whether to conduct a competitive requirement. No collect calls will be accepted.
- Place of Performance
- Address: NIH/NCI
- Zip Code: 20892
- Country: USA
- Zip Code: 20892
- Record
- SN00491152-W 20031219/031217211951 (fbodaily.com)
- Source
-
FedBizOpps.gov Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |